# Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

> **NCT03575104** · PHASE3 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 924 (actual)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** Daridorexant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03575104
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-29
- **Primary completion:** 2020-04-09
- **Final completion:** 2020-05-14
- **Target enrollment:** 924 (ACTUAL)
- **Last updated:** 2022-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575104, "Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03575104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*